NCT01438892已完成不适用
Impact Of RA Therapy Compliance On Patient-Reported Outcomes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 396
- 主要终点
- HAQ
研究概览
简要总结
Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.
详细描述
Cohort observational
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults with moderate to severe RA who are currently using a DMARD
排除标准
- •Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use
研究组 & 干预措施
tDMARDs Group
traditional DMARDs
干预措施: tDMARDs (Drug)
Biologics group
Biologics used in RA
干预措施: biodmards (Drug)
结局指标
主要结局
HAQ
时间窗: 12 months
36-Item Short-Form Health Survey (SF-36)
时间窗: 12 months
次要结局
- Compliance(12 months)
研究者
相似试验
已完成
不适用
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs BiologicsArthritis, RheumatoidNCT03964649Pfizer7,308
尚未招募
不适用
‘Comparison of costs and patient reported outcomes of endovenous techniques in the treatment of incompetent saphenous veins;’A single center, double blinded, randomized controlled trial.varicose veins, endovenous treatment, VNUS, endolaserNL-OMON22362no sponsor70
已完成
不适用
Health Outcomes in Rheumatoid ArthritisRheumatoid ArthritisNCT00346411Johns Hopkins University164
尚未招募
不适用
Measuring the therapy-effect of a mandibular repositioning appliance (MRA): A new method.mild-to-moderate Obstructive Sleep Apnea Syndrome (OSAS)NL-OMON26447Medical Spectrum Twente, Enschede15
已完成
4 期
A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)HIVNCT01445223Göteborg University242